| # | Title | Journal | Year | Citations |
|---|
| 1 | 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis | Annals of the Rheumatic Diseases | 2017 | 1,220 |
| 2 | Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database | Annals of the Rheumatic Diseases | 2010 | 1,017 |
| 3 | Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study | Annals of the Rheumatic Diseases | 2014 | 633 |
| 4 | Mapping and predicting mortality from systemic sclerosis | Annals of the Rheumatic Diseases | 2017 | 410 |
| 5 | The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles | Proceedings of the National Academy of Sciences of the United States of America | 2005 | 368 |
| 6 | Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group | Annals of the Rheumatic Diseases | 2011 | 330 |
| 7 | Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis | Circulation Research | 2004 | 276 |
| 8 | Chemokine Secretion of Rheumatoid Arthritis Synovial Fibroblasts Stimulated by Toll-Like Receptor 2 Ligands | Journal of Immunology | 2004 | 253 |
| 9 | Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis | Autoimmunity Reviews | 2020 | 231 |
| 10 | Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers | Arthritis Research | 2002 | 230 |
| 11 | TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort | Annals of the Rheumatic Diseases | 2018 | 220 |
| 12 | Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo11Principal Investigators: D. Uebelhart, MD, Assistant Professor; M. Malaise, MD, Professor, R. Marcolongo, MD, Professor; E. Vignon, MD, Professor. Co-Investigators: M. Piperno, MD, Head Physician; E. Mailleux, MD, Head Physician; A. Fioravanti, MD, Head Physician; L. Matoso, MD, Physician; Statistical analysis: F. DeVathaire, PhD, Professor; Radiological analys | Osteoarthritis and Cartilage | 2004 | 218 |
| 13 | Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation | Rheumatology | 1997 | 215 |
| 14 | The EuroMyositis registry: an international collaborative tool to facilitate myositis research | Annals of the Rheumatic Diseases | 2018 | 183 |
| 15 | β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis | Annals of the Rheumatic Diseases | 2012 | 174 |
| 16 | Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis | Annals of the Rheumatic Diseases | 2014 | 168 |
| 17 | Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database | Annals of the Rheumatic Diseases | 2021 | 160 |
| 18 | Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis | Arthritis and Rheumatism | 2004 | 158 |
| 19 | Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study | PLoS ONE | 2016 | 158 |
| 20 | The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review | Autoimmunity Reviews | 2017 | 153 |
| 21 | Epigenetic control in rheumatoid arthritis synovial fibroblasts | Nature Reviews Rheumatology | 2009 | 135 |
| 22 | The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index | Annals of the Rheumatic Diseases | 2017 | 132 |
| 23 | The release of microparticles by apoptotic cells and their effects on macrophages | Apoptosis: an International Journal on Programmed Cell Death | 2005 | 127 |
| 24 | Down‐regulation of microRNA‐34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance | Arthritis and Rheumatism | 2012 | 123 |
| 25 | PU.1 controls fibroblast polarization and tissue fibrosis | Nature | 2019 | 121 |
| 26 | Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) | Annals of the Rheumatic Diseases | 2021 | 120 |
| 27 | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial | Lancet Respiratory Medicine,the | 2021 | 118 |
| 28 | Falls prediction in elderly people: A 1-year prospective study | Gait and Posture | 2010 | 116 |
| 29 | Delays in assessment of patients with rheumatoid arthritis: variations across Europe | Annals of the Rheumatic Diseases | 2011 | 112 |
| 30 | Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis | European Journal of Immunology | 1998 | 108 |
| 31 | COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD | Annals of the Rheumatic Diseases | 2020 | 107 |
| 32 | The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts | Immunity | 2021 | 106 |
| 33 | Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis | Autoimmunity Reviews | 2019 | 101 |
| 34 | Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model | Annals of the Rheumatic Diseases | 2018 | 100 |
| 35 | Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis | Arthritis Research and Therapy | 2009 | 99 |
| 36 | Myocarditis in Humans and in Experimental Animal Models | Frontiers in Cardiovascular Medicine | 2019 | 99 |
| 37 | Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis | Annals of the Rheumatic Diseases | 2013 | 98 |
| 38 | Animal models for arthritis: innovative tools for prevention and treatment | Annals of the Rheumatic Diseases | 2011 | 92 |
| 39 | Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling | Annals of the Rheumatic Diseases | 2015 | 92 |
| 40 | Systemic sclerosis: state of the art on clinical practice guidelines | RMD Open | 2019 | 91 |
| 41 | Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells | Arthritis and Rheumatism | 2006 | 89 |
| 42 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis | Nature Communications | 2018 | 89 |
| 43 | EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells | Annals of the Rheumatic Diseases | 2009 | 87 |
| 44 | 18F-Fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis | European Journal of Nuclear Medicine and Molecular Imaging | 2010 | 84 |
| 45 | Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis | Science Signaling | 2014 | 84 |
| 46 | Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells | Frontiers in Cardiovascular Medicine | 2019 | 83 |
| 47 | A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study | Annals of the Rheumatic Diseases | 2016 | 82 |
| 48 | Fast track algorithm: How to differentiate a “scleroderma pattern” from a “non-scleroderma pattern” | Autoimmunity Reviews | 2019 | 79 |
| 49 | Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort | Annals of the Rheumatic Diseases | 2019 | 79 |
| 50 | Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis | Annals of the Rheumatic Diseases | 2005 | 78 |
